A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

por Benson, C, White, J, Bono, J De, O'Donnell, A, Raynaud, F, Cruickshank, C, McGrath, H, Walton, M, Workman, P, Kaye, S, Cassidy, J, Gianella-Borradori, A, Judson, I, Twelves, C
Publicado 2007